{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:29Z","timestamp":1786987529280,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.critrevonc.2024.104443","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T20:19:54Z","timestamp":1721161194000},"page":"104443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0126-8418","authenticated-orcid":false,"given":"Sebastian","family":"Ochenduszko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslawa","family":"Puskulluoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pacholczak-Madej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreto","family":"Ruiz-Millo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104443_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vhri.2018.12.003","article-title":"Back to the future: in the era of cost-effectiveness analysis, affordability is a limiting factor for patients\u2019 access to innovative cancer treatments","volume":"20","author":"Aguiar","year":"2019","journal-title":"Value Heal Reg. Issues"},{"key":"10.1016\/j.critrevonc.2024.104443_bib2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib3","doi-asserted-by":"crossref","first-page":"S656","DOI":"10.1016\/j.annonc.2023.09.2223","article-title":"1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III\/IV melanoma: 7-y results from CheckMate 238","volume":"34","author":"Ascierto","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eclinm.2023.102290","article-title":"Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study","volume":"65","author":"Bai","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2024.104443_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/13696998.2019.1609485","article-title":"Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States","volume":"22","author":"Bensimon","year":"2019","journal-title":"J. Med Econ."},{"key":"10.1016\/j.critrevonc.2024.104443_bib6","first-page":"1","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Bottomley","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.26921","article-title":"Association of circulating tumor DNA With disease-free survival in breast cancer: a systematic review and meta-analysis","volume":"3","author":"Cullinane","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2024.104443_bib11","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","article-title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma","volume":"116","author":"Eggermont","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104443_bib13","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib14","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104443_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2024.104443_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III Melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2024.104443_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.21037\/atm.2017.08.10","article-title":"Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM)","volume":"5","author":"Espinosa","year":"2017","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/13696998.2023.2174748","article-title":"Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland","volume":"26","author":"Favre-Bulle","year":"2023","journal-title":"J. Med Econ."},{"key":"10.1016\/j.critrevonc.2024.104443_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2024.104443_bib21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2024.104443_bib22","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2024.104443_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.20.01762","article-title":"Lessons from ADAURA on adjuvant cancer drug trials: evidence, ethics, and economics","volume":"39","author":"Gyawali","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib25","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study","volume":"115","author":"Helgadottir","year":"2023","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2024.104443_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104443_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.critrevonc.2024.104443_bib28","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib29","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104443_bib30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/jnci\/djad125","article-title":"Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials","volume":"115","author":"Li","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2024.104443_bib31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104443_bib32","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2217\/imt-2016-0039","article-title":"Emerging biomarkers as predictors to anti-PD1\/PD-L1 therapies in advanced melanoma","volume":"8","author":"Loo","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2024.104443_bib34","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1007\/s12325-023-02484-3","article-title":"Cost-effectiveness of pembrolizumab as an adjuvant treatment in colombia for melanoma patients with lymph node involvement after complete resection","volume":"40","author":"Lopez-Vinueza","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2024.104443_bib35","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib36","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104443_bib37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Rapid increase in reporting of fatal immune checkpoint inhibitor associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104443_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16058","article-title":"Cost per event averted in cancer trials in the adjuvant setting from 2018 to 2022","volume":"5","author":"Mousavi","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2024.104443_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100303","article-title":"Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation","volume":"6","author":"Mulder","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2024.104443_bib40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib41","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib42","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.3390\/ijerph20064926","article-title":"Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists","volume":"20","author":"Pacholczak-Madej","year":"2023","journal-title":"Int J. Environ. Res Public Health"},{"key":"10.1016\/j.critrevonc.2024.104443_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib44","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1875639","article-title":"A multicenter characterization of hepatitis associated with immune checkpoint inhibitors","volume":"10","author":"Patrinely","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2024.104443_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib47","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.20.00995","article-title":"Five-year outcomes with nivolumab in patients with Wild-Type BRAF advanced melanoma","volume":"38","author":"Robert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib48","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib49","doi-asserted-by":"crossref","first-page":"12613","DOI":"10.3390\/ijms241612613","article-title":"The future of precision oncology","volume":"24","author":"Rulten","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104443_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104443_bib51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2217\/cer.15.38","article-title":"Systematic overview of cost-effectiveness thresholds in ten countries across four continents","volume":"4","author":"Schwarzer","year":"2015","journal-title":"J. Comp. Eff. Res"},{"key":"10.1016\/j.critrevonc.2024.104443_bib52","article-title":"Common Terminology Criteria for Adverse Events","author":"Services","year":"2020","journal-title":"Definitions"},{"key":"10.1016\/j.critrevonc.2024.104443_bib53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s41669-023-00391-5","article-title":"Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067","volume":"7","author":"Shao","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.critrevonc.2024.104443_bib54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jnci\/djx133","article-title":"Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy","volume":"110","author":"Suciu","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2024.104443_bib55","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1200\/JCO.2023.41.16_suppl.9577","article-title":"Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB\/C\/IV melanoma treated with adjuvant immunotherapy in Checkmate 238","volume":"41","author":"Syeda","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib56","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib57","first-page":"1","article-title":"Predictive factors for immunotherapy in melanoma","volume":"3","author":"Teixid\u00f3","year":"2015","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib58","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1200\/JCO.2022.40.16_suppl.8533","article-title":"Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non\u2013small cell lung cancers","volume":"40","author":"Tian","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2024.104443_bib59","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104443_bib60","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2021.08.028","article-title":"Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma","volume":"158","author":"Weber","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104443_bib62","doi-asserted-by":"crossref","first-page":"TPS9616","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9616","article-title":"INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma","volume":"42","author":"Weber","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2024.104443_bib63","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104443_bib64","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00262-022-03302-5","article-title":"Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival","volume":"72","author":"Weber","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2024.104443_bib65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40487-021-00142-8","article-title":"Cost-effectiveness of pembrolizumab for the adjuvant treatment of melanoma patients with lymph node involvement who have undergone complete resection in argentina","volume":"9","author":"Wurcel","year":"2021","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.critrevonc.2024.104443_bib67","doi-asserted-by":"crossref","first-page":"S910","DOI":"10.1016\/j.annonc.2022.07.926","article-title":"800P Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant (Adj) therapies for resected stage (St) II-III melanoma","volume":"33","author":"Zara","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104443_bib68","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1007\/s12325-023-02525-x","article-title":"Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of resected stage IIB or IIC melanoma in the United States","volume":"40","author":"Zhang","year":"2023","journal-title":"Adv. Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T20:12:28Z","timestamp":1725480748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":68,"alternative-id":["S1040842824001860"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104443","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104443"}}